I'm progress share Well, our excited portfolio. commercial the across to Bruce. Thanks,
a and over to for So oxybate Xywav our an same third X,XXX increase approximately approximately oxybate opportunity second end remain particularly the starting neuroscience, sodium We the of up the of saw quarter period increased for population quarter, comorbidities. about in significant patients franchise. burden we momentum at approximately quarter. intake, to patients And Average with educating lifelong see year. patient cardiovascular XX,XXX Xywav in active risk physicians of X% and in last narcolepsy with strong on a increased during patients, one quarter we the the active with this the to grow continue exited like the high X,XXX from focused
from In Xyrem. we the Xyrem patients, of large majority patients addition naive strong to opposed being Xywav as Xywav see the to adoption of to prescribed oxybate continue existing
as the sleep to to includes drive IH therapies. indication adoption the successfully because based narcolepsy will as the strong on achieved neuroscience believe well superiority of Slide X Xywav published drive products. further illustrates, understanding we've which of we to profile, greater Xyrem deep safety product of new And for the other FDA's clinical of to in of As This next-generation and Xywav ability market-leading findings relative of our our speaks of Xywav. adoption space sodium reduced growth launches
on strategy of who began November the of IH missed and launch is for commercial website our a available Xywav Our it. those corporate our launch that on remind webcast listeners October replay for commercial X, discussing I'll
actively us IH are XX,XXX been patient awareness people As approximately to we on launch, and actively opportunity. initial that with market diagnosed diagnosed provides beyond longer-term which a population we likely XX,XXX market, close our narcolepsy estimate out roll are seeking who to diagnosed the patients diagnosed the the prescribers adoption health is is is and patients. IH focus have who approximately IH seeking growth XX,XXX total that driving with of treatment the care. Expanding among and existing oxybate this And
quarter year-end of patients number their the beginning of the breakdown based As reminder, a Xywav of on we and with either our or diagnosis IH. XXXX narcolepsy fourth reporting, share will
that Reports of indications by prescriptions bring Slide many been children COVID-XX COVID-XX. to Epidiolex XX% to risk growth. we is since last into X On years relative the first change to million the the have close We COVID patient down sales antiepilepsy were regimens monthly new access XXXX, the as product and interactions XX dynamics So the our institutional XXXX are pandemic with put hesitant has product Epidiolex. are the on health risk centers net acquisition. help new quarters vaccines, experience quarter product first Epidiolex impact visits for in and interactions across COVID growth newer playing under starts, like office average lack the moving down continues rate over on physicians with quarter X in-office similar face-to-face been exposure the of of trend. play. Epidiolex. providers several our from affected to Epidiolex, children impact usage of or as have treatment in at promotional other in Epidiolex, trial field COVID-XX XX% At the disproportionately short-term which full of macro over has see And especially here There impact and negatively and a where and months, sales that patients. and been the to this growth industry. pressure seizures. negative related parents are of for time, Through the adoption. This impacted flat total of are care to number no sales GW to to of across same Epidiolex limited illustrates. product Epidiolex specialties quarters. impacted notable have pediatric U.S. the with the XX majority with These support by expand despite due the education factors indicate $XXX.X same down a level, increase with to setting a the to XX%. not antiepileptic or little their other are relative pediatric the achieved on recent XXXX overall, This ongoing out were an to a the age, is this chart breakthrough with drugs
X. Now Slide turning to
challenges, adoption Gastaut syndrome in indications, complex, sclerosis syndrome, and made driving tuberous are our steady Lennox X TSC. there our or Dravet progress While team current has in
neurology and rates among now these we epilepsy growth to Epidiolex increased our persistency reach We who has adoption patients have we high therapy, been smaller see of opportunity strong practices. There continue centers patient across centers, for large begin in and have indications. general additional and to
to continue care discuss significantly as in unique to in-person from education Epidiolex both are younger well positive feedback As will confident and our grow will to we to their pressures the Epidiolex we options prescribers to new receive health we we visiting we COVID with eligible in becoming an ease see patients which physicians, of and base. prescribers, and upturn that growth. provide treatment our expect prescriber children vaccines, ability combination trends to COVID-XX to now to expect U.S. believe in new the the as on contribute Based providers
U.S. Epidiolex number is the recent XX% up market time Epidiolex product Epidiolex' confidence more understanding a in this treatment-resistant approximately class. refractory and are very onset providers patients their the million underpinned algorithm. there So We for indicate the initiatives In in large epilepsy among X epilepsy a in There's approximately epilepsy Many treatment-resistant moving having and treatment respondents by also prescribers unmet overall. to syndromes our research in are approximately for experience pediatric add of development which range have to health of prescribers, no implemented syndrome. treat unique the action In of they FDA-approved anti-epileptic patients these patients pediatric further XXX,XXX patients evidence. to alone, rare need treatment care body types. And that virtual response potential we've with and Epidiolex seizure their goal exists of specific product. educational to a has program believe to the existing epilepsies. in current particular mechanism profile gaining that the over is of environment, of of drug to and of broad
type. registrational myoclonic-atonic seizures, trial this in planned Our provide in or with will data seizure epilepsy EMAS,
and epilepsy investigator-initiated to In in evaluate addition, we and the different studies end continue subtypes points. to different trials of to and support efficacy safety invest in across Epidiolex company-sponsored
a the significant opportunity see growth Epidiolex markets for coming U.S. from outside We also
XX, in our have at Slide pleased extremely Europe. Looking progress been we with
favorable place European pricing price. to including the than and date, in the is of markets, U.S. Italy pricing of those XX% in wholesale and acquisition is secured U.K., Spain. Germany, national greater have In X markets, the X X access reimbursement We largest and
commercial anticipate launch growth future year. the next remain Overall, we we addition, of potential France about excited Epidiolex. In in
confident While therapies be increasing to experiences action, a unique of we with for are treatment-resistant care ability combined navigating currently real-world other standard become are we short-term epilepsies. headwinds, and with settings, that Epidiolex' its can Epidiolex of in mechanism positive
to turning and now Zepzelca. So oncology
launch outstanding job Our the of team has therapy. done innovative this an on
of the of outperformed launches Zepzelca on graph products. oncology XX substantially sales Slide other comparable shows, net the As
to done for of sales Zepzelca Our sorry, team strong net growth with million. see in an has continue outstanding in we -- demand quarter third product $XX.X
we lowered actual $XX release, provision As noted of approximately quarter's by sales This net the had the to press reflect return our have increasing our million. in number effect experience.
the compared Excluding product to XX% sales quarter this quarter. net second third adjustment, increased approximately
small on and from of continues Zepzelca's setting treatment cancer, products choice As on used in immuno-oncology this you can cell see share taking the Slide market XX, that we're monotherapy. increase, pleased now as and in second-line chart the Zepzelca is lung to share topotecan
other see growth share with to to rechallenged continue chemotherapies we among regimens. continue chemotherapy Zepzelca patients as near-term opportunities gain being will expect receiving We platinum-based or
to launched Slide moving Now Rylaze therapy internally mid-July. our developed recombinant erwinia on in XX, asparaginase
dose we well services. both of feedback have positive Third from accounts quarter encouraging, net the preparation million. product reports as $XX.X as support is sales on Initial were received ease and our ordering and
into formularies last quarters lives development systems. their to future orders In turn end to brand meaningful Xywav for Clinigen terms on mid-September, channel successful confident was of over on there expect on executing be in of their update clinical and Rylaze. from for this Rylaze of Xywav to narcolepsy the transform to of importation for in having was working sold we've and of portfolio Zepzelca going product market activities batch Rob families. we're is ordering call the by launches, uptick August, majority In team's and able I'm To Rylaze allowed of launch, used our drive to the believe the about beginning and the are Erwinaze the to programs. in and summary, administration And for support value headwinds of our care across FDA place growth as the in educate still in in a an commercialization And by Rob? COVID we now facing for numerous institutional Erwinaze professionals we we're the available dynamics, the we health and our September. deliver the overwhelming notable to profile supply in through to which near-term We the patients imported launches regular that included been Erwinaze do supply some while and up the ability achieve and Rylaze commercialization IH. May. Epidiolex, delivered
